Drug intelligence / Profile preview

Cyclophosphamide, Docetaxel, and Thiotepa Combination

Development stage: Unknown
Lead developer: Takeda
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

The combination of cyclophosphamide, docetaxel, and thiotepa is a high-dose chemotherapy regimen primarily used in the treatment of metastatic breast cancer. This combination leverages the synergistic effects of these three agents to target cancer cells through different mechanisms.

Targets

TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on Cyclophosphamide, Docetaxel, and Thiotepa Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclophosphamide, Docetaxel, and Thiotepa Combination.

Explore the full profile